A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)
Completed · Phase 1/Phase 2
Conditions studied: Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
In brief
The primary objectives of this study are to determine the safety and efficacy of brexucabtagene autoleucel (KTE-X19) in adult participants with relapsed/refractory (r/r) B-precursor acute lymphoblastic leukemia (ALL).
Key facts
- Study ID
- NCT02614066
- Run by
- Kite, A Gilead Company
- People needed
- 125
- Starts
- 2016-03-07
- Expected to finish
- 2023-11-03
- Last updated by the study team
- 2024-11-19
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- UC San Diego-Moores Cancer Center — La Jolla, California, United States
- University of California Los Angeles (UCLA) — Los Angeles, California, United States
- University of California Irvine Medical Center — Orange, California, United States
- University of California Davis Comprehensive Cancer Center — Sacramento, California, United States
- University of California San Francisco — San Francisco, California, United States
- H Lee Moffitt Cancer Center — Tampa, Florida, United States
- Emory University — Atlanta, Georgia, United States
- Loyola University — Chicago, Illinois, United States
- University of Chicago — Chicago, Illinois, United States
- University of MD Greenbaum Comprehensive Cancer Center — Baltimore, Maryland, United States
- Dana Farber Cancer Institute — Boston, Massachusetts, United States
- Mayo Clinic — Rochester, Minnesota, United States
- Washington University School of Medicine — St Louis, Missouri, United States
- Mount Sinai Tisch Cancer Institute — New York, New York, United States
- Memorial Sloan-Kettering Cancer Center — New York, New York, United States
- University of Rochester — New York, New York, United States
- Sarah Cannon — Nashville, Tennessee, United States
- Vanderbilt-Ingram Cancer Center — Nashville, Tennessee, United States
- Baylor Charles A. Sammons Cancer Center — Dallas, Texas, United States
- University of Texas MD Anderson Cancer Center — Houston, Texas, United States
- Swedish Cancer Institute — Seattle, Washington, United States
- Seattle Cancer Center — Seattle, Washington, United States
- University Health Network - Princess Margaret — Toronto, Ontario, Canada
- Institut Paoli Calmettes — Marseille, France
- Hopital Saint Louis — Paris, France
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.